PRA buys out Takeda JV in Japan

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Pra health sciences, Takeda, Japan

PRA Health Sciences has bought out its joint venture with Takeda, establishing a new subsidiary based in Japan – a rapidly growing market, says EVP.

PRA Health Sciences K.K. is now operating as a PRA subsidiary in Japan following PRA Health Sciences buyout of its joint venture with Takeda Pharmaceutical Company Limited, which was established in 2017.

The addition of Takeda’s staff increases PRA’s totals employee numbers to 450 in Japan, with the opportunity for additional growth in the near term, according to the company.

Including the PRA’s new offices in Tokyo and Osaka, the company currently has more than 2,300 staff members across 15 countries in the Asia region.

“Our vision is to be the premier pharma partner in Japan by expanding our operations and expertise across therapeutic areas and functions to serve Japan and the entire Asia Pacific region,”​ said Samir Shah, executive vice president and president, strategic solutions at PRA Health Sciences.

“Asia is the third largest market for biopharmaceutical outsourcing, and Japan is rapidly growing. PRA has made an investment in the region reflective of the business opportunity,”​ he told us.

As for integration, Dr. Atsushi Ogawa, president and representative director of PRA Japan, said the process is progressing “steadily and smoothly.” ​The company is already conducting in-house work and providing services to clients, including Takeda, he told us.

“PRA Japan provides flexible infrastructure, end-to-end clinical development across all phases, embedded solutions, and technology and data science,”​ Ogawa added.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars